• Enzymatica signed a long-term exclusive ColdZyme distribution agreement with MMDS-backed MedonyX for Jordan and Iraq on October 21, 2026.
• The deal marks its first entry into the Middle East and North Africa, targeting markets with a combined population of nearly 58 million.
• Launches in both countries are expected in the first quarter of 2027, subject to local regulatory approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enzymatica AB published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.